Background: Obstetric morbidity (OM) is a common feature of antiphospholipid syndrome (OAPS). Women having OAPS-only and women with OM related to antiphospholipid antibodies (aPL) but not fulfilling APS classification criteria (OMAPS), may show similar patterns. Aim: The aim of this research was to collect records of OAPS and OMAPS cases in order to have valuable information about their clinical features, laboratory, treatment, pregnancy outcomes and long-term follow-up. Methods: EUROAPS/EUROMAPS is a registry in the frame of the European Forum on Antiphospholipid Antibody projects. Its own website has been available since June 2010: www.euroaps.org. Results: This registry comprises 211 women including 304 pre-enrolment pregnancies, and 226 prospective cases, 194 of OAPS and 32 of OMAPS. OM was more frequent in OAPS than in OMAPS, independent of treatment. In the prospective cohort, standard aPL data was available in 202 cases and treatment data in all 226 cases. Good fetal outcomes were obtained when low dose aspirin plus low molecular weight heparin were administered. Prevalence of thrombotic events and/or cases evolving into full-blown systemic lupus erythematosus (SLE) was low. Conclusions: OAPS could be a different form of APS. OMAPS/OMAPS fetal outcomes were better when treated. The prevalence of thrombosis and progression to SLE were lower than in ‘classical’ APS.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost2006; 4: 205–306.
2.
OutHJKooijmanCDBruinseHW. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynaecol Report Biol1991; 195: 211–220.
3.
GirardiGRedechaPSalmonJE. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nature Med2004; 10: 1222–1226.
4.
Alijotas-ReigJIzquiedoMSerraB. Antiphospholipid autoantibodies, complement levels, hypergammaglobulinemia and spontaneous intrauterine haematomas in pregnant women. Am J Reprod Immunol2003; 49: 1–6.
5.
CarboneJSarmientoERodriguez-MolinaJ. Hipocomplementemia C3 y C4 en el síndrome antifosfolípido obstétrico. Rev Clin Esp2008; 208: 168–171.
6.
SalmonJEGirardiG. Antiphospholipid syndrome revisited: a disorder initiated by inflammation. Lupus2007; 16(abst suppl): 1–2.
7.
GirardiGRedechaPSalmonJE. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nature Med2004; 10: 1222–1226.
8.
BermanJGirardiGSalmonJE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol2005; 174: 1222–1226.
9.
ChuAJ. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct2006; 24: 173–192.
10.
GirardiGYarilinDThurmanJM. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med2006; 203: 2165–2175.
11.
BoffaM-CBoinotCde CarolisS. Laboratory criteria of the obstetrical antiphospholipid syndrome (APS). Data from a multicentre prospective European women cohort. Thromb Haemost2009; 102: 25–28.
12.
Alijotas-ReigJVilardell-TarrésM. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?Obstet Gynecol Surv2010; 65: 39–45.
13.
BranchW. on behalf of the Obstetric Task Force. Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus2011; 20: 158–164.
14.
Boffa MC. Diagnostic criteria for APS. Results of a questionnaire of the European Forum on Antiphospholipid Antibodies. VII European forum on aPL, Marseille, France, 2–3 October 2009. (Oral Communication).
